The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1Contributed by: Business WireLogoTagsResearchInfectious DiseasesNeurologyClinical TrialsBiotechnologyGeneral HealthPharmaceuticalHealthScienceOncologyTakeda Pharmaceutical, New England Journal of Medicine